Validation of the GenoType® MTBDRplus assay for detection of MDR-TB in a public health laboratory in Thailand by Anek-vorapong, Rapeepun et al.
Anek-vorapong et al. BMC Infectious Diseases 2010, 10:123
http://www.biomedcentral.com/1471-2334/10/123
Open Access RESEARCH ARTICLE
BioMed  Central
© 2010 Anek-vorapong et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
Research article Validation of the GenoType® MTBDRplus assay for 
detection of MDR-TB in a public health laboratory 
in Thailand
Rapeepun Anek-vorapong1,4, Chalinthorn Sinthuwattanawibool2,4, Laura Jean Podewils*3,4, Kimberly McCarthy3,4, 
Keerataya Ngamlert1,4, Busakorn Promsarin1,4 and Jay K Varma2,3,4
Abstract
Background: Over the past several years, new diagnostic techniques have been developed to allow for the rapid 
detection of multidrug resistant tuberculosis. The GenoType® MTBDRplus test is a deoxyribonucleic acid (DNA) strip 
assay which uses polymerase chain reaction (PCR) and hybridization to detect genetic mutations in the genes that 
confer isoniazid (INH) and rifampn (RIF) resistance. This assay has demonstrated good performance and a rapid time to 
results, making this a promising tool to accelerate MDR-TB diagnosis and improve MDR-TB control. Validation of rapid 
tests for MDR-TB detection in different settings is needed to ensure acceptable performance, particularly in Asia, which 
has the largest number of MDR-TB cases in the world but only one previous report, in Vietnam, about the performance 
of the GenoType® MDRplus assay. Thailand is ranked 18th of 22 "high-burden" TB countries in the world, and there is 
evidence to suggest that rates of MDR-TB are increasing in Thailand. We compared the performance of the GenoType® 
MTBDRplus assay to Mycobacterial Growth Indicator Tube for Antimycobacterial Susceptibility Testing (MGIT AST) for 
detection INH resistance, RIF resistance, and MDR-TB in stored acid-fast bacilli (AFB)-positive sputum specimens and 
isolates at a Public TB laboratory in Bangkok, Thailand.
Methods: 50 stored isolates and 164 stored AFB-positive sputum specimens were tested using both the MGIT AST and 
the GenoType® MTBDRplus assay.
Results: The GenoType® MTBDRplus assay had a sensitivity of 95.3%, 100%, and 94.4% for INH resistance, RIF resistance, 
and MDR-TB, respectively. The difference in sensitivity between sputum specimens (93%) and isolates (100%) for INH 
resistance was not statistically significant (p = 0.08). Specificity was 100% for all resistance patterns and for both 
specimens and isolates. The laboratory processing time was a median of 25 days for MGIT AST and 5 days for the 
GenoType® MTBDRplus (p < 0.01).
Conclusion: The GenoType® MTBDRplus assay has been validated as a rapid and reliable first-line diagnostic test on 
AFB-positive sputum or MTB isolates for INH resistance, RIF resistance, and MDR-TB in Bangkok, Thailand. Further 
studies are needed to evaluate its impact on treatment outcome and the feasibility and cost associated with 
widespread implementation.
Background
Drug-resistant tuberculosis (TB) has emerged as an
important global public health threat. The World Health
Organization (WHO) estimates that 489,000 cases of
multi-drug resistant TB (MDR-TB), defined as infection
with a Mycobacterium tuberculosis (MTB) strain resistant
to at least isoniazid (INH) and rifampin (RIF), occur
annually, predominantly in Eastern Europe and Asia [1].
Treatment involves prolonged use of "second-line" anti-
TB drugs that are less effective, less tolerated, more toxic,
and more expensive than "first-line" anti-TB medications
[2]. Under optimum program conditions, cure rates for
drug-susceptible TB exceed 90%; for MDR-TB, cure rates
infrequently exceed 70% [3]. In most high-burden TB
countries, MDR-TB is only diagnosed after prolonged
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treatment with first-line TB drugs and clinical recogni-
tion that treatment has failed. Treatment of drug-resis-
t a n t  T B  w i t h  s t a n d a r d  f i r s t - l i n e  d r u g s ,  i n s t e a d  o f  a
regimen designed according to the resistance pattern, has
several potential adverse consequences: patients remain
on inadequate treatment longer, increasing the risk of
treatment failure or death; regimens inadequate to kill
MTB amplify resistance to drugs to which their isolates
were previously susceptible; and patients remain infec-
tious, promoting transmission to close contacts [4].
Because of this problem, the WHO is recommending that
countries immediately expand their capacity for culture-
based drug-susceptibility testing (DST) and consider
new, molecular-based assays for diagnosing drug resis-
tance [5,6].
The internationally accepted gold standard for MDR-
TB diagnosis is demonstration of MTB growth in cul-
tures inoculated with INH and RIF. Even using modern
broth-based culture systems, obtaining DST results from
sputum specimens still takes several weeks [7]. New
assays have been developed to detect resistance faster
using genotype, rather than phenotype. The GenoType®
MTBDRplus test is a deoxyribonucleic acid (DNA) strip
assay which uses polymerase chain reaction (PCR) and
hybridization to detect mutations in the inhA, katG, and
rpoB  genes that confer INH and RIF resistance [8]. A
recent meta-analysis found that the GenoType®  MTB-
DRplus assay and one other similar commercial test have
a pooled sensitivity of 98% for detecting RIF resistance
and 89% for detecting INH resistance [9]. Specificity
averages 99% for RIF and INH [9]. Testing can be per-
formed on isolates or AFB-positive sputum specimens
and can return results in 8 hours, making this a promising
tool to accelerate MDR-TB diagnosis and improve MDR-
TB control.
Although the GenoType® MTBDRplus assay has been
studied in several laboratories, there is wide variation in
circulating MTB strains across the globe [10,11], and false
negative results occur due to unique genetic mutations
[9,12-17]. Validation in different settings is needed to
ensure acceptable performance, particularly in Asia,
which has the largest number of MDR-TB cases in the
world but only one previous report, in Vietnam, about the
performance of the GenoType® MDRplus assay [18]. Thai-
land is 18th on the list of 22 "high-burden" TB countries in
the world, with over 90,000 cases occurring annually [19].
A national survey in 2002 found that the rate of MDR-TB
was 1% in previously untreated TB patients and 20% in
previously treated patients; a second survey in 2006
found that the rate of MDR-TB had increased to 1.7% in
previously untreated patients and 34.5% in previously
treated patients [20]. We have previously validated the
feasibility and performance of broth-based culture and
DST at the Bangkok city public TB laboratory in Thailand
[7]. In this study, we compared the performance of the
GenoType® MTBDRplus to a broth-based DST assay for
detecting INH resistance, RIF resistance, and MDR-TB in
AFB-positive sputum specimens and isolates in the same
laboratory.
Methods
Setting
Between July and September 2008, we evaluated the per-
formance characteristics of the GenoType® MTBDRplus
assay at the Bangkok Metropolitan Administration
(BMA) Health Laboratory Division, the primary clinical
laboratory for the city's TB control program. Before study
implementation, we tested 50 MTB isolates of known
resistance patterns from WHO's External Quality Assur-
ance program to evaluate laboratory proficiency in using
this assay. After this, the performance characteristics of
the GenoType® MTBDRplus assay were assessed in two
populations: (a) 50 stored MTB isolates with known
resistance patterns to INH and/or RIF from pulmonary
TB patients in Bangkok; and (b) 164 stored acid fast
bacilli (AFB)-positive sputum specimens that were sub-
mitted to the BMA laboratory by 163 TB patients for rou-
tine culture and DST. All MGIT AST results were blinded
to the microbiologists performing the GenoType® MTB-
DRplus assay.
Routine testing of sputum specimens
Sputum specimens were processed using the U.S. Centers
for Disease Control and Prevention (US CDC) recom-
mended method of N-acetyl-L-cysteine 4% NaOH-2.9%
citrate (final concentration of NaOH 1%). Following incu-
bation at room temperature for 15 minutes, specimens
were concentrated, decanted, re-suspended, and then
examined for the presence of AFB using Ziehl-Neelsen
(ZN) method. The remaining suspension was used to
inoculate two Lowenstein-Jensen (LJ) tubes and one
Mycobacterial Growth Indicator Tube (MGIT, Becton-
Dickinson). Residual processed sputum was frozen at -
70°C and used for GenoType® MTBDRplus testing. MGIT
cultures were incubated in the MGIT BACTEC 960 for
six weeks. All cultures flagged as positive were removed,
examined for AFB using ZN staining, and subcultured to
LJ and confirmed as MTB using classical biochemical
tests including niacin accumulation, nitrate reduction,
and inhibition to para-nitrobenzoic (PNB) acid [20]. All
isolates identified as MTB underwent MGIT AST for
INH, RIF, streptomycin, and ethambutol, using previ-
ously described methods [7]. All positive MGIT vials
were stored at room temperature for the duration of the
assessment to allow discrepant testing.
DNA isolation from clinical specimens and MTB isolates
AFB positive sputum specimens graded as scanty, 1+, 2+
and 3+ were prepared for the GenoType® MTBDRplusAnek-vorapong et al. BMC Infectious Diseases 2010, 10:123
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assay by first concentrating 500 μL of the residual pro-
cessed specimen in a microcentrifuge (10,000 × g, 15
minutes, room temperature). The supernatants were
decanted and the pellet was re-suspended in 100 μL of
distilled water, then inactivated by incubating the bacte-
ria in a heating block for 20 minutes at 95°C. Cells were
sonicated in an ultrasonic bath for 15 minutes, and con-
centrated for an additional 5 minutes. The supernatants
were transferred to a new tube to be stored for PCR.
Isolates were prepared for the GenoType® MTBDRplus
assay by first sub-culturing stored clinical strains to broth
culture then to LJ. We then used approximately 1 loop full
of colonies taken from the LJ to prepare a bacterial sus-
pension in 300 μL of distilled water. This suspension was
inactivated, sonicated and concentrated using the same
procedures applied to sputum specimens.
DNA amplification
Amplification was performed by combining 35 μL of
primer nucleotide mix (PNM) with 5 μL of 10× PCR buf-
fer (containing 15 mM MgCl2), 2 μL MgCl2 (25 mM
MgCl2), 3 μL molecular grade H2O, 0.2 μL (1 unit) Hot-
Star Taq polymerase (QIAGEN, Hilden, Germany), and 5
μL of the bacterial suspension for a total final volume of
50.2 μL. The amplification profile for direct patient mate-
rial as described by the manufacturer was used for all
bacterial suspensions. First, the template DNA was dena-
tured for 15 minutes at 95°C, followed by 10 cycles con-
sisting of 30 s at 95°C and 2 minutes at 58°C, with an
additional 30 cycles consisting of 25 s at 95°C, 40 s at 53°C
and 40 s at 70°C. The final cycle consisted of an 8 minute
run at 70°C.
Hybridization
Hybridization was performed manually using a shaking
water bath/Twincubator®  preheated to 45°C. Twenty
microliters of denaturation solution were mixed thor-
oughly in a plastic 12-well tray with 20 μL of amplified
sample and incubated at room temperature for 5 minutes.
One milliliter of hybridization buffer was added to each
well and mixed. We then placed 1 pre-labeled test strip
into each well, and incubated the test strips and solutions
for 30 minutes at 45°C. All solutions were completely
aspirated following incubation. One milliliter of stringent
wash solution was then added to each strip and incubated
for 15 minutes at 45°C. Once all solutions were com-
pletely aspirated, we applied 1 mL of rinse solution to
each strip for 1 minute. The rinse solution was then com-
pletely removed and 1 mL of diluted conjugate was added
to each strip, and incubated for 30 minutes. After incuba-
tion, all solutions were removed, and the test strips were
rinsed twice by using a rinse solution for 1 minute, fol-
lowed by distilled water for 1 minute. All solutions were
completely aspirated between rinses. We then added 1
mL of diluted substrate to each strip and incubated the
test strips protected from light for up to 20 minutes. All
solutions were removed, and the reaction was stopped by
rinsing twice with distilled water. The test strips were
allowed to dry, and then taped to the GenoType® MTB-
DRplus assay worksheet for interpretation.
Repeat testing and discrepant analysis
Sputum specimens and isolates resulting in inconsistent
development of bands on the MTBDRplus strip, and/or
no MTB control band underwent repeat PCR and hybrid-
ization from the extracted DNA. Isolates with discrepan-
cies between the susceptibility results of the GenoType®
MTBDRplus assay and MGIT AST were sent to US CDC
for sequencing.
Statistical analyses
The time from positive culture in the laboratory to the
time DST results were read was calculated using the Gen-
oType® MTBDRplus assay and the MGIT AST method for
each specimen. All statistical tests were performed using
Stata 10.0 (College Station, TX). Statistical significance
was established at an alpha level of 0.05.
Ethical review
This project underwent formal ethical review at the U.S.
CDC and Bangkok Metropolitan Administration. It was
approved as a public health program evaluation, not
requiring individual informed consent.
Results
Phenotypic testing identified INH resistance in 14/50
(28%) isolates and in 29/164 (18%) sputum specimens,
and RIF resistance in 6/50 (12%) isolates and in 19/164
(12%) sputum specimens. The GenoType® MTBDRplus
assay had a sensitivity of 95.3% (41/43), 100% (25/25), and
94.4% (17/18) for INH-resistance, RIF-resistance, and
MDR-TB, respectively (Tables a1a and b1b). Of the 41
specimens that were identified as INH-resistant using the
GenoType® MTBDRplus assay, 32 had a mutation in the
katG gene, 6 in the inhA gene, and 3 in both genes. For
INH resistance, the sensitivity was lower for sputum
specimens (93%) than for isolates (100%), but the differ-
ence was not statistically significant (p = 0.08). Specificity
was 100% for all resistance patterns and for both speci-
mens and isolates. We were able to obtain interpretable
sequence data for one of two sputum specimens with
INH resistance detected by conventional testing but not
molecular testing; this isolate was identified as wild type.
For the 211 specimens with dates recorded for time
from the culture result to the DST result, the laboratory
processing time for the GenoType® MTBDRplus assay was
significantly shorter than MGIT AST: 5 days compared
with 25 days (p < 0.01) (Table 2). The most markedAnek-vorapong et al. BMC Infectious Diseases 2010, 10:123
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Table 1: Performance characteristics of the GenoType® MTBDRplus assay.
A. Performance characteristics of the GenoType® MTBDRplus assay for the detection of RIF- and INH-resistance in comparison to drug-
susceptibility test results using the MGIT BACTEC 960.
INH Resistance RIF Resistance
MGIT AST Result MGIT AST Result
Specimen Type GenoType®
MTBDRplus Result
+ - Sensitivity
(%)
Specificity 
(%)
+ - Sensitivity 
(%)
Specificity 
(%)
AFB+ Sputum + (Resistant) 27 0 93.1 100 19 0 100 100
- (Sensitive) 21 3 5 0 1 4 5
Stored Isolate + 14 0 100 100 6 0 100 100
- 03 6 0 4 4
All Specimens + 41 0 95.3 100 25 0 100 100
- 21 7 1 0 1 8 9
B. Performance characteristics of the GenoType® MTBDRplus assay for the detection of MDR-TB in comparison to drug-susceptibility
test results using the MGIT BACTEC 960.
MDR-TB
MGIT AST Result
Specimen Type GenoType®
MTBDRplus Result
+ - Sensitivity
(%)
Specificity 
(%)
AFB+ Sputum + (Resistant) 12 0 92.3 100
- (Sensitive) 11 5 1
Stored Isolate + 5 0 100 100
- 04 5
All Specimens + 17 0 94.4 100
- 11 9 6
+ = Resistant; - = Sensitive
advantage in laboratory processing time was evident
when specimens were processed directly from AFB-posi-
tive sputum smears (3 days vs. 24.5 days; p < 0.01).
Discussion
In Bangkok, the GenoType® MTBDRplus  detected INH
resistance, RIF resistance, and MDR-TB with a high sen-
sitivity and 100% specificity in both isolates and AFB-
positive sputum specimens, with substantial reductions
in turn-around time compared with MGIT AST.
This study provides assurance that TB patients in Thai-
land with MDR-TB detected with the GenoType® MTB-
DRplus assay should immediately commence treatment
with second-line anti-TB drugs. The 100% specificity cor-
responds to a positive likelihood ratio of near infinity,
suggesting that, regardless of the pre-test odds of MDR-
TB, the post-test odds from a positive test are sufficiently
high to warrant MDR-TB treatment. Ideally, the Geno-
Type® MTBDRplus assay should be performed on AFB-
positive sputum specimens, rather than isolates, to take
advantage of the more than three week acceleration in
turn-around-time. Use of the assay on AFB-positive spu-
tum and rapid commencement of MDR-TB treatment for
patients with genotypic resistance has the potential to
improve patient outcomes, reduce TB transmission, and
reduce amplification of resistance to first-line drugs (e.g.,Anek-vorapong et al. BMC Infectious Diseases 2010, 10:123
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ethambutol, pyrazinamide, and streptomycin) to which
the isolate may not yet be resistant.
One weakness of the GenoType® MTBDRplus is the lack
of 100% sensitivity for MDR-TB, attributable to the test's
failure to detect all mutations that confer INH resistance.
Two AFB-positive sputum specimens were confirmed as
INH resistant by MGIT AST and sensitive by the Geno-
Type® MTBDRplus. We were able to obtain interpretable
sequence data of the promoter region for inhA and katG
for one specimen which confirmed the result of the Gen-
oType® MTBDRplus. INH resistance in this strain may be
due to mutations in regions other than codon 315 of katG
or nucleic acid positions -15, -16 and -8 in the inhA pro-
moter region; or mutations in genes not represented on
the test strip, such as ahpC-oxyR, and ndh [21,22]. How-
ever, a recent evaluation of 160 INH resistant isolates in
Thailand found that 92.5% (148) of the gene mutations
were found in codon 315 of katG and the inhA promoter
and coding regions (127 and 22, respectively) [23]. These
findings support the utility of the GenoType® MTBDRplus
assay for detecting the majority of genetic mutations con-
ferring INH resistance in Thailand. As we were not able
to obtain quality sequencing results for our second speci-
men, the reason for the discordance remains unclear.
Advances in understanding the molecular epidemiology
of INH resistance may contribute to improved test per-
formance.
Our validation study was conducted using stored spu-
tum specimens and isolates from TB patients in Thailand.
Therefore, our turn around time using the GenoType®
MTBDRplus for identification of RIF and INH resistance
in AFB positive sputum specimens is based on the time
from confirmed AFB positive smear results to interpreta-
tion of the GenoType® MTBDRplus. The turn around time
for isolates is based on the time required to subculture
strains of MTB, obtain growth, perform and interpret
results of the GenoType® MTBDRplus assay. On average,
results were available using GenoType® MTBDRplus on
AFB-positive sputum specimens in 3 days and in 16 days
f or  isola t es;  c om pa r ed wit h 2 5 da ys usi ng M GIT  AS T .
Our laboratory uses the manual method for the Geno-
Type® MTBDRplus assay and performs DNA extraction
and PCR on the first day and hybridization on the second
d a y .  I n t e r p r e t a t i o n  o f  t h e  t e s t  s t r i p s  r e q u i r e d  a n  a d d i -
tional 1-2 days. Laboratories with adequate staff may
r e d u c e  t h e i r  t u r n  a r o u n d  t i m e  b y  p e r f o r m i n g  D N A
extraction, PCR, and hybridization in one day, and by
using the automated system (GT-Blot 48; Hain Life-
Science GmbH, Germany). Turn around time from speci-
men collection to susceptibility result will be determined
during the implementation phase of our study.
This study evaluated a large number of sputum speci-
mens at a routine public health facility in a high-burden
TB setting. Most evaluations of the GenoType® MTB-
DRplus assay have involved a relatively small number of
specimens (usually less than 50) and were conducted in
primarily academic facilities located in low TB burden,
high income countries [9,12-17]. The only other evalua-
tion that involved a large number of samples from a pub-
lic health facility in a high-burden TB country was done
in South Africa [16,17]. Test performance in 536 sputum
specimens was similar to our findings, although the test
showed the additional ability to detect MTB and drug-
resistant MTB in smear-negative, culture-positive speci-
mens. The major limitation of our study is that it involved
a relatively small number of sputum specimens compared
Table 2: Comparison of laboratory processing times using the GenoType® MTBDRplus assay and the MGIT BACTEC 960 for 
drug-susceptibility testing.
MGIT BACTEC 960 GenoType® MTBDRplus
Specimen Type Culture Result to 
Identification
median days 
(IQR)
DST Initiation to 
DST Result
median days 
(IQR)
Total Time from 
Culture to DST
median days 
(IQR)
DNA Extraction 
to DST Result
median days 
(IQR)
Total Time from 
Culture Result to 
DST
median days 
(IQR)
Direct Sputum + 15 (12 - 19) 9 (7 - 11) 24.5 (21 - 29) 3 (2 - 5) N/A
Stored
Isolate
14 (12.5 - 19.5) 9 (7 - 12) 25 (21 - 28.5) 2 (1.5 - 2) 16 (14 - 21)
All Local 
Specimens
15 (12 - 19) 9 (7 - 11) 25 (21 - 29) 2 (1 - 3) 5 (3 - 9)*
IQR = interquartile range (25th and 75th percentile)
* Pooled for all specimens: for direct sputum AFB+ time from DNA extraction to DST result; for isolates time from culture result to DST result.Anek-vorapong et al. BMC Infectious Diseases 2010, 10:123
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with the number routinely processed in the laboratory,
which may have been an insufficient sample to detect dif-
ferences in test performance between isolates and AFB-
positive sputum.
In conclusion, the GenoType® MTBDRplus  assay has
been validated as a rapid and reliable first-line diagnostic
test on AFB-positive sputum or MTB isolates for INH
resistance, RIF resistance, and MDR-TB in Bangkok,
Thailand. Whether it should be implemented into routine
public health programmatic use, however, is not yet clear.
Further studies are needed to evaluate its impact on treat-
ment outcome and the feasibility and cost associated with
widespread implementation.
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